Kernal Biologics GTM brain

Kernal Biologics develops targeted mRNA and lipid nanoparticle therapies for cancer and autoimmune disease and seeks development partners.

category

Targeted mRNA therapeutics and in vivo CAR-T

market profile

  • text: Cell therapies face manufacturing, cost and specialist-center constraints; in vivo programming is an investigational approach to address them.
  • text: Kernal's targeted LNP and mRNA CAR-T platform is in preclinical development, with therapeutic efficacy and safety still to be established in humans.
  • text: Biopharma collaborations can combine delivery and nucleic acid platforms with partners' disease expertise and development resources.

personas

  • title: Biopharma business development and licensing leader
    pains:
    • Needs differentiated external platforms and programs that fit oncology or autoimmune strategy.
    • Must evaluate scientific maturity, intellectual property and partnership economics before committing.
  • title: Head of cell therapy or translational research
    pains:
    • Ex vivo cell therapy manufacturing is complex and limits access.
    • Targeted delivery and cell-specific expression require evidence of selectivity, efficacy and safety.
  • title: Oncology and autoimmune clinical development leader
    pains:
    • Patients with serious disease need better treatment options.
    • Preclinical promise must translate to a credible clinical development path.

icp

  • text: Pharmaceutical and biotechnology companies developing oncology or autoimmune therapeutics and seeking targeted delivery or cell therapy collaborations.
  • text: Research and clinical development organizations with expertise and resources to advance investigational mRNA-LNP programs.

message pillars

  • text: Combine targeted delivery with cell-selective expression to engineer cells in the body.
  • text: Address limitations of current cell therapy manufacturing and access through investigational in vivo programming.
  • text: Tailor partnerships to complementary expertise and the needs of each program.

objections

  • objection: Is the platform clinically validated?
    response: The cited independent review describes Kernal's in vivo CAR-T platform as preclinical; request detailed data and development milestones rather than assume clinical efficacy.
  • objection: How will off-target effects and tolerability be evaluated?
    response: Review the underlying selectivity, biodistribution and preclinical safety data under diligence, including model limitations.
  • objection: How would a partnership be structured?
    response: The company says collaborations are tailored to each program; scope rights, responsibilities and milestones directly.

competitors

  • name: Capstan Therapeutics
    why: Develops targeted in vivo CAR-T approaches using lipid nanoparticles.
  • name: Vyriad
    why: Develops targeted in vivo CAR-T programs with a different delivery approach.
  • name: Starna Therapeutics
    why: Develops targeted LNP and mRNA in vivo CAR-T therapies.

influencers

  • name: Yusuf Erkul
    url: https://www.kernalbio.com/about
    why: CEO and cofounder representing the scientific and partnering strategy.

keywords

  • in vivo CAR T therapy
  • targeted lipid nanoparticle delivery
  • mRNA cell selective translation
  • T cell targeted LNP
  • autoimmune CAR T development
  • oncology mRNA partnerships
  • in vivo cell engineering

voice

  • scientific and technically specific
  • patient-outcome oriented
  • collaborative and ambitious

signals

  • text: A biopharma team is seeking external in vivo CAR-T or targeted mRNA delivery partnerships.
  • text: A company is expanding cell therapy development in hematologic cancer or autoimmune disease.

stack

  • mRNA
  • lipid nanoparticles
  • AI-designed mRNA

pricing

model: unknown

motion

sales_led

channels

  • scientific conferences
  • biopharma partnerships
  • research publications
  • industry press

confidence

medium

Founders

  • name: Yusuf Erkul
    title: Founder
    role: Founder
    bio: I'm co-founder and CEO of Kernal Biologics, a Boston-based biotech startup developing next-generation messenger RNA immunotherapy. Backed by Hummingbird, Amgen, Lilly, NVIDIA, HBM, NASA, and Boeing, Kernal Bio raised more than $30M. Early in my career, I worked at Merck&Co. on the discovery and development of various oncology drugs, including ZEJULA®, which got FDA approval for ovarian cancer. I hold an executive MBA from MIT Sloan, an M.D. from Hacettepe Univ. and a B.S. in Biology from MIT.
  • name: Jeff Ozdemir
    title: Founder
    role: Founder
    bio: I got PhD in Molecular Genetics at UTSW Medical Center at Dallas. I moved to Boston for postdoctoral training at Harvard Medical School. I served as Biochemistry instructor at MIT. Then I joined Kernal as a co-founder.
  • name: Burak YILMAZ
    title: Founder
    role: Founder
    bio: My name is Burak Yilmaz, MS, co-founder, and lead designer of Kernal Biologics. As a synthetic biologist, I co-invented stealth and onco-selective mRNA platform technology in Kernal. Kernal is my second endeavor. Previously, I founded Sentegen/Sentebiolab which is a synthetic biology company that produces synthetic DNA for research and diagnostic purposes.

Back to YC companies